Skip to main content
Ensol Biosciences Inc. logo

Ensol Biosciences Inc. — Investor Relations & Filings

Ticker · 140610 ISIN · KR7140610007 KO Manufacturing
Open in API
Filings indexed 257 across all filing types
Latest filing 2026-01-23 Regulatory Filings
Country KR South Korea
Listing KO 140610

About Ensol Biosciences Inc.

https://www.ensolbio.co.kr/eng/

Ensol Biosciences Inc. is a biopharmaceutical company focused on developing innovative drugs for diseases with limited or no therapeutic alternatives. The company leverages a bio big data and AI-driven platform for its research and development activities. A core area of its technology involves Protein-Protein Interaction (PPI)-regulating short peptide drugs, which are designed for local injection to maximize therapeutic effects and minimize systemic side effects through high specificity and a short half-life in the blood. The company's pipeline targets a range of medical unmet needs, including degenerative disc disease, osteoarthritis, cancer, and neurodegenerative disorders like Alzheimer's disease. Key clinical-stage assets include E1K for osteoarthritis (preparing for Phase 3) and C1K, an anticancer combination therapy (Phase 1).

Recent filings

Filing Released Lang Actions
임상시험단계진입ㆍ종료(자율공시)
Regulatory Filings Classification · 95% confidence The document is a regulatory filing from Ensol Biosciences regarding the approval of a Phase 3 clinical trial for their osteoarthritis drug, E1K. It details the clinical trial objectives, background, approval history, and future plans. Since this is a specific regulatory announcement regarding clinical trial status (a material event for a biotech company) and does not fit into the other specific categories like financial reports or shareholder meetings, it is classified as a Regulatory Filing (RNS).
2026-01-23 Korean
주주명부폐쇄기간또는기준일설정
Notice of Dividend Amount Classification · 95% confidence The document is a short regulatory announcement regarding the setting of a record date for the purpose of determining shareholders eligible to vote at the upcoming Annual General Meeting (AGM). It does not contain the full meeting materials or proxy statements, but rather serves as a formal notice of the record date. Given the nature of the announcement and the lack of a specific category for 'Record Date' notices, it falls under the general regulatory filing category.
2025-12-16 Korean
기업설명회(IR)개최결과
Investor Presentation Classification · 90% confidence The document is titled '기업설명회(IR) 개최 결과' which translates to 'Investor Relations (IR) Meeting Results'. It details the date, time, location, attendees, main contents, and confirmation agencies related to an IR event held on 2025-10-31. The content focuses on the event summary and logistics rather than presenting financial statements or detailed financial analysis. The document length is short (945 characters), and it reports on the occurrence and results of an IR meeting rather than providing the full report or transcript. Therefore, it fits best under the category of Investor Presentation (IP), as it relates to a presentation for investors focusing on company status and outlook, even though it is a summary of the event rather than the full presentation itself. Given the nature and content, confidence is high.
2025-10-31 Korean
기업설명회(IR)개최
Investor Presentation Classification · 95% confidence The document is an announcement of an upcoming investor relations event (기업설명회(IR) 개최), specifying date, time, location, participants, and agenda. It does not contain actual financial data or detailed financial analysis but rather informs about the event and that IR materials will be posted later. The document length is short (1002 characters), and it serves as a notice rather than a report or transcript. Therefore, it fits the category of Investor Presentation (IP) as it relates to a presentation for investors focusing on company status and outlook.
2025-10-14 Korean
임원ㆍ주요주주특정증권등소유상황보고서
Director's Dealing Classification · 100% confidence The document is titled '임원ㆍ주요주주 특정증권등 소유상황보고서' which translates to 'Report on Ownership Status of Specific Securities by Executives and Major Shareholders.' It details the ownership changes of securities by a specific individual, including dates, number of shares, and ownership percentages. The document is addressed to regulatory bodies such as the Securities and Futures Commission and the Korea Exchange, indicating it is a regulatory disclosure. The content focuses on insider shareholdings and transactions by a director or major shareholder, not on financial results, management changes, or other report types. This matches the definition of 'Director's Dealing' (DIRS), which covers reports of personal share transactions by company directors and executives (insider trades). The document length is 2816 characters, which is consistent with a detailed insider transaction report rather than a full financial report or announcement. Therefore, the correct classification is DIRS with high confidence.
2025-10-02 Korean
주식등의대량보유상황보고서(약식)
Major Shareholding Notification Classification · 100% confidence The document is a '주식등의 대량보유상황보고서' (Report on Large Shareholding), which is a standard regulatory filing in South Korea under the Capital Markets Act. It details changes in share ownership by a major shareholder (Hyung Inwoo) and their special related party (Yeom Hyeyoon) in the company Ensol Biosciences. This type of filing is specifically categorized as a 'Major Shareholding Notification' (MRQ) in the provided schema, as it tracks changes in significant ownership levels.
2025-08-08 Korean

Browse filings by year

9 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.